Nitzan Rosenfeld

Last updated
Nitzan Rosenfeld

FMedSci
Alma mater Weizmann Institute of Science.
Scientific career
InstitutionsCancer Research UK Cambridge Institute, University of Cambridge, Inivata
Website www.cruk.cam.ac.uk/research-groups/rosenfeld-group

Nitzan Rosenfeld FMedSci is a professor of Cancer Diagnostics at the University of Cambridge. He is a Senior Group Leader at the Cancer Research UK Cambridge Institute and co-founder of Inivata, a clinical cancer genomics company.

Contents

Education

Nitzan trained in Physics, and specialized in quantitative molecular biology, obtaining a Ph.D. in the field of Systems Biology from the Weizmann Institute of Science. [1]

Research and career

After completing his Ph.D., Rosenfeld began working in translational research within Rosetta Genomics Ltd, a leading company in microRNA-based diagnostic tests for cancer. [2]

In 2009 he joined the Cancer Research UK Cambridge Institute at the University of Cambridge. Within his first year, his laboratory became one of the few worldwide to obtain accurate data on circulating tumour DNA (ctDNA) in patient plasma. [3]

His team was first to develop and demonstrate effective methods of gene panel sequencing of cell-free plasma DNA. [4] They went on to demonstrate the utility of exome-wide sequencing for analysis of ctDNA. [5]

Targeted sequencing of plasma DNA has since become widely used in cancer research and diagnostics. His team and clinical collaborators demonstrated the ability to use ctDNA to study tumour heterogeneity and evolution, [6] and provided key evidence for the utility of ctDNA in monitoring cancer response and progression. [7]

Their key publication in the New England Journal of Medicine demonstrated the advantages of ctDNA over other biomarkers, notably circulating tumor cells. [8] These accumulated achievements played a significant role in the explosive growth of the ctDNA field. [9]

Rosenfeld is the co-founder and Chief Scientific Officer of Inivata Ltd., one of the UK's leading genomics companies that was amongst the first to offer clinical liquid biopsy tests for cancer genomic profiling. [10]

Awards and honours

In 2013, Professor Rosenfeld was awarded the Cancer Research UK Future Leaders in Cancer Research Prize and the British Association for Cancer Research Translational Research Award. [11]

He was awarded the Foulkes Foundation Medal in 2015 from the Academy of Medical Sciences for outstanding bioscience research. [3]

Rosenfeld was awarded the 2020 Pezcoller Foundation – EACR Cancer Researcher Award, celebrating academic excellence and achievements in the field of translational cancer research. [12]

He was elected Fellow of the Academy of Medical Sciences [13] in 2020. His citation on election reads:

"Nitzan Rosenfeld is a Senior Group Leader at Cancer Research UK Cambridge Institute. He is a pioneer and world leader in developing liquid biopsy tests for cancer using circulating tumour DNA. He has developed multiple clinical diagnostic tests for cancer, based on microRNA expression profiling and on circulating cell-free tumour DNA in plasma. He co-founded Inivata Ltd., one of the UK's leading genomics companies that was amongst the first to offer clinical liquid biopsy tests for cancer genomic profiling. His research group continues to develop sensitive methods for detection of cell free tumour DNA in body fluids, and ways to apply these for cancer detection and monitoring."

Related Research Articles

<span class="mw-page-title-main">Biopsy</span> Medical test involving extraction of sample cells or tissues for examination

A biopsy is a medical test commonly performed by a surgeon, interventional radiologist, or an interventional cardiologist. The process involves extraction of sample cells or tissues for examination to determine the presence or extent of a disease. The tissue is then fixed, dehydrated, embedded, sectioned, stained and mounted before it is generally examined under a microscope by a pathologist; it may also be analyzed chemically. When an entire lump or suspicious area is removed, the procedure is called an excisional biopsy. An incisional biopsy or core biopsy samples a portion of the abnormal tissue without attempting to remove the entire lesion or tumor. When a sample of tissue or fluid is removed with a needle in such a way that cells are removed without preserving the histological architecture of the tissue cells, the procedure is called a needle aspiration biopsy. Biopsies are most commonly performed for insight into possible cancerous or inflammatory conditions.

Noninvasive genotyping is a modern technique for obtaining DNA for genotyping that is characterized by the indirect sampling of specimen, not requiring harm to, handling of, or even the presence of the organism of interest. Beginning in the early 1990s, with the advent of PCR, researchers have been able to obtain high-quality DNA samples from small quantities of hair, feathers, scales, or excrement. These noninvasive samples are an improvement over older allozyme and DNA sampling techniques that often required larger samples of tissue or the destruction of the studied organism. Noninvasive genotyping is widely utilized in conservation efforts, where capture and sampling may be difficult or disruptive to behavior. Additionally, in medicine, this technique is being applied in humans for the diagnosis of genetic disease and early detection of tumors. In this context, invasivity takes on a separate definition where noninvasive sampling also includes simple blood samples.

Dr. Paul R. Billings is a distinguished American doctor, lecturer, researcher, professor, and consultant on genetic information. His research interests include the impact of genomic data on society, the integration of genomics with diagnostics in health and medical care, and individualized genomic medicine. He is the author of over 250 publications and has appeared on talk shows such as The Oprah Winfrey Show and 60 Minutes. He is currently the CEO and Director of Biological Dynamics.

<span class="mw-page-title-main">Molecular diagnostics</span> Collection of techniques used to analyze biological markers in the genome and proteome

Molecular diagnostics is a collection of techniques used to analyze biological markers in the genome and proteome, and how their cells express their genes as proteins, applying molecular biology to medical testing. In medicine the technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients, and in agricultural biosecurity similarly to monitor crop- and livestock disease, estimate risk, and decide what quarantine measures must be taken.

Dennis Yuk Ming Lo is a Hong Kong molecular biologist, and an important contributor to the development of non-invasive prenatal testing. He is the current Associate Dean (Research) and Li Ka Shing Professor of Medicine at the Chinese University of Hong Kong (CUHK), as well as the head of the Department of Chemical Pathology of CUHK and the director of the Li Ka Shing Institute of Health Sciences. His research focuses on the detection of cell-free fetal DNA in blood plasma.

<span class="mw-page-title-main">Circulating tumor DNA</span> Tumor-derived fragmented DNA in the bloodstream

Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream that is not associated with cells. ctDNA should not be confused with cell-free DNA (cfDNA), a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin. Because ctDNA may reflect the entire tumor genome, it has gained traction for its potential clinical utility; "liquid biopsies" in the form of blood draws may be taken at various time points to monitor tumor progression throughout the treatment regimen.

A liquid biopsy, also known as fluid biopsy or fluid phase biopsy, is the sampling and analysis of non-solid biological tissue, primarily blood. Like traditional biopsy, this type of technique is mainly used as a diagnostic and monitoring tool for diseases such as cancer, with the added benefit of being largely non-invasive. Liquid biopsies may also be used to validate the efficiency of a cancer treatment drug by taking multiple samples in the span of a few weeks. The technology may also prove beneficial for patients after treatment to monitor relapse.

<span class="mw-page-title-main">Andrea Ablasser</span> German immunologist

Andrea Ablasser is a German immunologist, who works as a full professor of Life Sciences at the École Polytechnique Fédérale de Lausanne. Her research has focused on how the innate immune system is able to recognise virus-infected cells and pathogens.

CAncer Personalized Profiling by deep Sequencing (CAPP-Seq) is a next-generation sequencing based method used to quantify circulating DNA in cancer (ctDNA). The method was introduced in 2014 by Ash Alizadeh and Maximilian Diehn’s laboratories at Stanford, as a tool for measuring Cell-free tumor DNA which is released from dead tumor cells into the blood and thus may reflect the entire tumor genome. This method can be generalized for any cancer type that is known to have recurrent mutations. CAPP-Seq can detect one molecule of mutant DNA in 10,000 molecules of healthy DNA. The original method was further refined in 2016 for ultra sensitive detection through integration of multiple error suppression strategies, termed integrated Digital Error Suppression (iDES). The use of ctDNA in this technique should not be confused with circulating tumor cells (CTCs); these are two different entities.

Circulating free DNA (cfDNA) (also known as cell-free DNA) are degraded DNA fragments released to body fluids such as blood plasma, urine, cerebrospinal fluid, etc. Typical sizes of cfDNA fragments reflect chromatosome particles (~165bp), as well as multiples of nucleosomes, which protect DNA from digestion by apoptotic nucleases. The term cfDNA can be used to describe various forms of DNA freely circulating in body fluids, including circulating tumor DNA (ctDNA), cell-free mitochondrial DNA (ccf mtDNA), cell-free fetal DNA (cffDNA) and donor-derived cell-free DNA (dd-cfDNA). Elevated levels of cfDNA are observed in cancer, especially in advanced disease. There is evidence that cfDNA becomes increasingly frequent in circulation with the onset of age. cfDNA has been shown to be a useful biomarker for a multitude of ailments other than cancer and fetal medicine. This includes but is not limited to trauma, sepsis, aseptic inflammation, myocardial infarction, stroke, transplantation, diabetes, and sickle cell disease. cfDNA is mostly a double-stranded extracellular molecule of DNA, consisting of small fragments (50 to 200 bp) and larger fragments (21 kb) and has been recognized as an accurate marker for the diagnosis of prostate cancer and breast cancer.

Sarah-Jane Dawson is an Australian clinician-scientist. She is a consultant medical oncologist and head of the Molecular Biomarkers and Translational Genomics Laboratory at the Peter MacCallum Cancer Centre in Melbourne. Her current research interests are focused on the development of noninvasive blood-based biomarkers for clinical application, including early detection, risk stratification and disease monitoring in cancer management.

In biotechnology BEAMing, which stands for beads, emulsion, amplification, magnetics, is a highly sensitive digital PCR method that combines emulsion PCR and flow cytometry to identify and quantify specific somatic mutations present in DNA.

<span class="mw-page-title-main">Caroline Dive</span> Professor of Cancer Pharmacology

Caroline Dive is a British cancer research scientist. Dive is Professor of Cancer Pharmacology at the University of Manchester, Deputy Director of the Cancer Research UK (CRUK) Manchester Institute, Director of the CRUK Manchester Institute Cancer Biomarker Centre and co-director of the CRUK Lung Cancer Centre of Excellence. She is the current President of The European Association for Cancer Research (EACR).

PyClone is a software that implements a Hierarchical Bayes statistical model to estimate cellular frequency patterns of mutations in a population of cancer cells using observed alternate allele frequencies, copy number, and loss of heterozygosity (LOH) information. PyClone outputs clusters of variants based on calculated cellular frequencies of mutations.

Personalized onco-genomics (POG) is the field of oncology and genomics that is focused on using whole genome analysis to make personalized clinical treatment decisions. The program was devised at British Columbia's BC Cancer Agency and is currently being led by Marco Marra and Janessa Laskin. Genome instability has been identified as one of the underlying hallmarks of cancer. The genetic diversity of cancer cells promotes multiple other cancer hallmark functions that help them survive in their microenvironment and eventually metastasise. The pronounced genomic heterogeneity of tumours has led researchers to develop an approach that assesses each individual's cancer to identify targeted therapies that can halt cancer growth. Identification of these "drivers" and corresponding medications used to possibly halt these pathways are important in cancer treatment.

Sophia Genetics is a data-driven medicine software company with headquarters in Lausanne, Switzerland and Boston, Massachusetts. It provides genomic and radiomic analysis for hospitals, laboratories, and biopharma institutions. The company was ranked among the 50 smartest companies by the MIT Technology Review in 2017. The company went public on the Nasdaq in 2021, floating at $1.1B.

<span class="mw-page-title-main">Helmy Eltoukhy</span> American scientist and entrepreneur

Helmy Eltoukhy is an American scientist and a businessperson who co-founded startups Avantome and Guardant Health. He is best known for his contributions to genomics, semiconductor DNA sequencing, and personalized medicine. His startups were acquired by Illumina in 2008. Avantome was founded to develop and commercialize semiconductor-based DNA sequencing, during the race for the $1,000 genome. Guardant Health was founded to pioneer non-invasive liquid biopsy approaches for cancer diagnosis, monitoring, personalized medicine treatment, and research.

Professor James D Brenton is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute and Professor of Ovarian Cancer Medicine in the Department of Oncology, University of Cambridge. He is an Honorary Consultant in Medical Oncology at Addenbrooke's Hospital, Cambridge University Hospitals, Ovarian Cancer Domain Lead for the 100,000 Genomes Project by Genomics England, and co-founder and Clinical Advisor to Inivata Ltd, a clinical cancer genomics company.

Cancer Likelihood in Plasma (CLiP) refers to a set of ensemble learning methods for integrating various genomic features useful for the noninvasive detection of early cancers from blood plasma. An application of this technique for early detection of lung cancer (Lung-CLiP) was originally described by Chabon et al (2020) from the labs of Ash Alizadeh and Max Diehn at Stanford.

<span class="mw-page-title-main">Ruth March</span> British genomic scientist

Ruth Eleanor March is a British genomic scientist who is senior vice president of precision medicine at AstraZeneca. She specialises in precision medicine and oncology. During the COVID-19 pandemic, March developed a diagnostic test for COVID-19.

References

  1. ↑ "SELECTBIO – Exosomes and Microvesicles Speaker Biography". selectbiosciences.com. Retrieved 2023-03-17.
  2. ↑ Ltd, Rosetta Genomics (2007-04-12). "Rosetta Genomics to Present Advancements in Its Cup Diagnostic Development Program". GlobeNewswire News Room (Press release). Retrieved 2023-03-17.
  3. 1 2 "Foulkes Medal 2015 awarded to Dr Nitzan Rosenfeld". acmedsci.ac.uk. Retrieved 2023-03-17.
  4. ↑ Forshew, Tim; Murtaza, Muhammed; Parkinson, Christine; Gale, Davina; Tsui, Dana W. Y.; Kaper, Fiona; Dawson, Sarah-Jane; Piskorz, Anna M.; Jimenez-Linan, Mercedes; Bentley, David; Hadfield, James; May, Andrew P.; Caldas, Carlos; Brenton, James D.; Rosenfeld, Nitzan (2012-05-30). "Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA". Science Translational Medicine. 4 (136): 136ra68. doi:10.1126/scitranslmed.3003726. ISSN   1946-6234. PMID   22649089. S2CID   34723244.
  5. ↑ Murtaza, Muhammed; Dawson, Sarah-Jane; Tsui, Dana W. Y.; Gale, Davina; Forshew, Tim; Piskorz, Anna M.; Parkinson, Christine; Chin, Suet-Feung; Kingsbury, Zoya; Wong, Alvin S. C.; Marass, Francesco; Humphray, Sean; Hadfield, James; Bentley, David; Chin, Tan Min (2013). "Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA". Nature. 497 (7447): 108–112. Bibcode:2013Natur.497..108M. doi:10.1038/nature12065. ISSN   0028-0836. PMID   23563269. S2CID   205233580.
  6. ↑ Murtaza, Muhammed; Dawson, Sarah-Jane; Pogrebniak, Katherine; Rueda, Oscar M.; Provenzano, Elena; Grant, John; Chin, Suet-Feung; Tsui, Dana W. Y.; Marass, Francesco; Gale, Davina; Ali, H. Raza; Shah, Pankti; Contente-Cuomo, Tania; Farahani, Hossein; Shumansky, Karey (2015-11-04). "Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer". Nature Communications. 6 (1): 8760. Bibcode:2015NatCo...6.8760M. doi:10.1038/ncomms9760. ISSN   2041-1723. PMC   4659935 . PMID   26530965.
  7. ↑ Parkinson, Christine A.; Gale, Davina; Piskorz, Anna M.; Biggs, Heather; Hodgkin, Charlotte; Addley, Helen; Freeman, Sue; Moyle, Penelope; Sala, Evis; Sayal, Karen; Hosking, Karen; Gounaris, Ioannis; Jimenez-Linan, Mercedes; Earl, Helena M.; Qian, Wendi (2016-12-20). Mardis, Elaine Rene (ed.). "Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study". PLOS Medicine. 13 (12): e1002198. doi: 10.1371/journal.pmed.1002198 . ISSN   1549-1676. PMC   5172526 . PMID   27997533.
  8. ↑ Dawson, Sarah-Jane; Tsui, Dana W.Y.; Murtaza, Muhammed; Biggs, Heather; Rueda, Oscar M.; Chin, Suet-Feung; Dunning, Mark J.; Gale, Davina; Forshew, Tim; Mahler-Araujo, Betania; Rajan, Sabrina; Humphray, Sean; Becq, Jennifer; Halsall, David; Wallis, Matthew (2013-03-28). "Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer". New England Journal of Medicine. 368 (13): 1199–1209. doi: 10.1056/NEJMoa1213261 . ISSN   0028-4793. PMID   23484797.
  9. ↑ "2020 - NITZAN ROSENFELD". www.pezcoller.it. Retrieved 2023-03-17.
  10. ↑ "Leadership Team". Welcome to Inivata. Retrieved 2023-03-17.
  11. ↑ admin, C. P. L. (2013-06-24). "Nitzan Rosenfeld receives British Association for Cancer Research Translational Research Award". Cancer Research UK Cambridge Institute. Retrieved 2023-03-17.
  12. ↑ "The Pezcoller Foundation-EACR Translational Cancer Researcher Award | The European Association for Cancer Research". www.eacr.org. Retrieved 2023-03-17.
  13. ↑ "Prof. Nitzan Rosenfeld | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 2023-03-17.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.